KR20240150426A - 비경구 호흡 자극제 제형 - Google Patents
비경구 호흡 자극제 제형 Download PDFInfo
- Publication number
- KR20240150426A KR20240150426A KR1020247025381A KR20247025381A KR20240150426A KR 20240150426 A KR20240150426 A KR 20240150426A KR 1020247025381 A KR1020247025381 A KR 1020247025381A KR 20247025381 A KR20247025381 A KR 20247025381A KR 20240150426 A KR20240150426 A KR 20240150426A
- Authority
- KR
- South Korea
- Prior art keywords
- formulation
- compound
- substituted
- parenteral formulation
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163293985P | 2021-12-27 | 2021-12-27 | |
| US63/293,985 | 2021-12-27 | ||
| US202263313472P | 2022-02-24 | 2022-02-24 | |
| US63/313,472 | 2022-02-24 | ||
| PCT/US2022/053935 WO2023129502A1 (en) | 2021-12-27 | 2022-12-23 | Respiratory stimulant parenteral formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240150426A true KR20240150426A (ko) | 2024-10-15 |
Family
ID=86992921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247025381A Pending KR20240150426A (ko) | 2021-12-27 | 2022-12-23 | 비경구 호흡 자극제 제형 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230210857A1 (https=) |
| EP (1) | EP4456900A4 (https=) |
| JP (1) | JP2025501169A (https=) |
| KR (1) | KR20240150426A (https=) |
| AU (1) | AU2022426492A1 (https=) |
| CA (1) | CA3242509A1 (https=) |
| MX (1) | MX2024008162A (https=) |
| TW (1) | TW202333732A (https=) |
| WO (1) | WO2023129502A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230414624A1 (en) * | 2022-06-24 | 2023-12-28 | Enalare Therapeutics Inc. | Methods of treating neurological ventilatory insufficiency |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR199901968T2 (xx) * | 1996-12-24 | 1999-12-21 | Biogen, Inc. | Sabit s�v� interferon form�lleri. |
| US20120295911A1 (en) * | 2010-11-29 | 2012-11-22 | Galleon Pharmaceuticals, Inc. | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases |
| AU2011336764B2 (en) * | 2010-11-29 | 2017-02-23 | Galleon Pharmaceuticals, Inc. | Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases |
| DK2701684T3 (en) * | 2011-04-28 | 2017-09-18 | Platform Brightworks Two Ltd | Improved parenteral formulations of lipophilic pharmaceuticals and methods for their preparation and use |
| SG11201503505QA (en) * | 2012-11-15 | 2015-06-29 | Galleon Pharmaceuticals Inc | Novel orally bioavailable breathing control modulating compounds, and methods of using same |
| GB201502412D0 (en) * | 2015-02-13 | 2015-04-01 | Canbex Therapeutics Ltd | Therapeutic use |
-
2022
- 2022-12-23 WO PCT/US2022/053935 patent/WO2023129502A1/en not_active Ceased
- 2022-12-23 US US18/088,137 patent/US20230210857A1/en active Pending
- 2022-12-23 EP EP22917259.8A patent/EP4456900A4/en active Pending
- 2022-12-23 CA CA3242509A patent/CA3242509A1/en active Pending
- 2022-12-23 JP JP2024539090A patent/JP2025501169A/ja active Pending
- 2022-12-23 KR KR1020247025381A patent/KR20240150426A/ko active Pending
- 2022-12-23 AU AU2022426492A patent/AU2022426492A1/en active Pending
- 2022-12-23 MX MX2024008162A patent/MX2024008162A/es unknown
- 2022-12-27 TW TW111150221A patent/TW202333732A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022426492A1 (en) | 2024-07-18 |
| CA3242509A1 (en) | 2023-07-06 |
| EP4456900A1 (en) | 2024-11-06 |
| WO2023129502A1 (en) | 2023-07-06 |
| MX2024008162A (es) | 2024-09-17 |
| TW202333732A (zh) | 2023-09-01 |
| JP2025501169A (ja) | 2025-01-17 |
| US20230210857A1 (en) | 2023-07-06 |
| EP4456900A4 (en) | 2025-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230310440A1 (en) | Respiratory stimulant nasal formulations | |
| EP1371355B1 (en) | UV-protection formulations | |
| US20250032496A1 (en) | Methods of treating respiratory depression modulated by a non-opioid agent | |
| US20250114370A1 (en) | Methods and compositions for treating drug overdose | |
| JP2024517463A (ja) | ニコチンアミドアデニンジヌクレオチド（ｎａｄ）組成物、それらの製造方法、及びそれらの使用方法 | |
| KR20240150426A (ko) | 비경구 호흡 자극제 제형 | |
| US20230414624A1 (en) | Methods of treating neurological ventilatory insufficiency | |
| US20240238303A1 (en) | Large-conductance potassium channel modulators, compositions thereof, methods of manufacturing thereof, and methods of use thereof | |
| CN118829433A (zh) | 呼吸刺激剂肠胃外制剂 | |
| CA3217969A1 (en) | Nicotinamide adenine dinucleotide (nad) compositions, methods of manufacturing thereof, and methods of use thereof | |
| TW202529771A (zh) | 用於治療藥物過量的方法及組合物 | |
| HK40100733A (zh) | 疤痕治疗组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |